All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Does consolidation therapy with blinatumomab improve survival in newly diagnosed adult with B-ALL in MRD⁻ remission?

Featured
Jan 23, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in acute lymphoblastic leukemia.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub was pleased to speak to Mark R. Litzow, Mayo Clinic, Rochester, US. We asked, Does consolidation therapy with blinatumomab improve survival in newly diagnosed adult patients with B-ALL in MRD remission?

Does consolidation therapy with blinatumomab improve survival in newly diagnosed adult with B-ALL in MRD⁻ remission?

Litzow provides an update on the results from the ECON-ACRIN E1910 randomized phase III trial of blinatumomab on behalf of the National Cooperative Clinical Trial Network. He then discusses how the addition of blinatumomab to consolidation chemotherapy can improve overall survival in patients with newly diagnosed B-ALL who were MRD-negative after intensification chemotherapy without any safety concerns. He concludes that the addition of blinatumomab to consolidation chemotherapy represents a new standard of care for adult patients with MRD-negative B-ALL.